Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
2.761 CHF
309.97 M CHF
2.14 B CHF
96.49 M
About Neurocrine Biosciences, Inc.
Sector
Industry
CEO
Kyle W. Gano
Website
Headquarters
San Diego
Founded
1992
ISIN
US64125C1099
FIGI
BBG00LVF08S7
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where NB3 is featured.
Frequently Asked Questions
The current price of NB3 is 89.100 CHF — it has increased by 0.40% in the past 24 hours. Watch Neurocrine Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange Neurocrine Biosciences, Inc. stocks are traded under the ticker NB3.
We've gathered analysts' opinions on Neurocrine Biosciences, Inc. future price: according to them, NB3 price has a max estimate of 160.15 CHF and a min estimate of 99.30 CHF. Watch NB3 chart and read a more detailed Neurocrine Biosciences, Inc. stock forecast: see what analysts think of Neurocrine Biosciences, Inc. and suggest that you do with its stocks.
NB3 stock is 0.40% volatile and has beta coefficient of 0.67. Track Neurocrine Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Neurocrine Biosciences, Inc. there?
Today Neurocrine Biosciences, Inc. has the market capitalization of 10.88 B, it has increased by 3.67% over the last week.
Yes, you can track Neurocrine Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Neurocrine Biosciences, Inc. is going to release the next earnings report on Nov 4, 2025. Keep track of upcoming events with our Earnings Calendar.
NB3 earnings for the last quarter are 0.84 CHF per share, whereas the estimation was 0.77 CHF resulting in a 9.89% surprise. The estimated earnings for the next quarter are 1.26 CHF per share. See more details about Neurocrine Biosciences, Inc. earnings.
Neurocrine Biosciences, Inc. revenue for the last quarter amounts to 545.46 M CHF, despite the estimated figure of 518.79 M CHF. In the next quarter, revenue is expected to reach 600.70 M CHF.
NB3 net income for the last quarter is 85.29 M CHF, while the quarter before that showed 6.99 M CHF of net income which accounts for 1.12 K% change. Track more Neurocrine Biosciences, Inc. financial stats to get the full picture.
No, NB3 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 5, 2025, the company has 1.8 K employees. See our rating of the largest employees — is Neurocrine Biosciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Neurocrine Biosciences, Inc. EBITDA is 418.60 M CHF, and current EBITDA margin is 26.50%. See more stats in Neurocrine Biosciences, Inc. financial statements.
Like other stocks, NB3 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Neurocrine Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.